SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a biopharmaceutical company, is focused on developing and commercializing innovative therapeutics designed to treat life-threatening diseases. The company’s strategy is to in-license late-stage clinical products, and then develop them for commercialization throughout the world. SciClone simultaneously strives to increase revenues and important cash flow to fund the expansion of its business as well as the development of a worldwide product portfolio. For further information, visit the Company’s web site at www.sciclone.com.
- 17 years ago
QualityStocks
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Files NI 43-101 Technical Report Supporting Swanson Gold Project PEA
This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising.…
-
LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Executives Outline Positive PEA Results Plus Company’s Next Steps to Production in Investor Webinar
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid…
-
Versus Systems Inc. (NASDAQ: VS) Is ‘One to Watch’
Versus Systems operates a patented earned-rewards platform that integrates gamification with real-world incentives across digital…